Broadcast Date: Wednesday, October 30, 2024
Time: 8:00 am PT, 11:00 am ET, 16:00 CET
Artificial Intelligence (AI) and machine learning are transforming the worlds of biotechnology and pharma, particularly in the arena of drug discovery. Leveraging the rise of large datasets and massive compute power, AI appears poised to expedite and, in some cases, reimagine the design of novel and more effective therapeutics, from cell and gene therapy, oncology, neuroscience, and more.
In GEN’s inaugural virtual summit, The State of AI in Drug Discovery, we proudly host an outstanding group of thought-leaders, researchers and AI entrepreneurs across industry and academia to showcase the latest advances, challenges and concerns regarding the deployment of AI in biotech, with particular emphasis on disrupting the drug discovery process. This exciting event brings together founders and executives from many of the most exciting companies powering the AI revolution, including Recursion, 1910 Genetics, Profluent, Terray Therapeutics, Generate:Biomedicines, and more!
Please join us on October 30th for a dynamic program featuring:
- A keynote presentation with protein design expert David Baker, PhD (University of Washington/HHMI)
- A keynote fireside chat with Najat Khan, PhD (Recursion) on growing the AI in drug discovery industry
- From computational platforms to protein design with Ava Amini, PhD (Microsoft Research), Gevorg Grigoryan, PhD (Generate: Biomedicines), Karen Akinsanya, PhD (Schrödinger)
- Foundational models to read and write the language of biology with Ali Madani, PhD (Profluent), Brian Hie, PhD (Arc Institute), and Alex Rives, PhD (EvolutionaryScale)
- Key considerations for AI-based small molecule drug discovery with experts from 1910 Genetics, Terray Therapeutics, insitro, and Insilico Medicine
- AI in drug discovery’s evolving business landscape with Simon Barnett (Dimension), Sabrina Yang, PhD (Empress Therapeutics/Flagship Pioneering) and Colin Hill (Aitia Bio)
- Breakout sessions from our event sponsors
Registration for The State of AI in Drug Discovery is entirely free.
Guest Speakers Include
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
IVIEW Therapeutics Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001, Exploring New Innovations in Dry Eye Disease and Gene Therapy
Cranbury, N.J., September 17, 2024 – IVIEW Therapeutics Inc., a clinical-stage biotechnology company known for advancing innovative therapies, including gene therapy, has successfully completed patient recruitment for its Phase 1/2 clinical trial evaluating IVW-1001....
Vironexis Biotherapeutics Launches with FDA Clearance for First AAV-Delivered Cancer Immunotherapy Trial
SAN DIEGO, Calif., September 12, 2024 – Vironexis Biotherapeutics has launched from stealth, announcing FDA clearance of its IND application for VNX-101, a gene therapy targeting CD19+ acute lymphoblastic leukemia. This marks the first-ever clinical trial of an...
Biotech Industry Trends in 2024: A Look at the Billions in Oncology Deals
In the global biotech sector, oncology has been a key focus of research and development (R&D) deals. Recent years have seen over $200 billion in transactions within this field, with $100 billion occurring in 2022 alone. Despite a peak in deal volume during 2020...
MinervaX and Wacker Collaborate on Manufacturing Prophylactic Group B Streptococcus Vaccine
MinervaX, a privately-held Danish biotechnology company developing a vaccine against Group B Streptococcus (GBS), and Wacker Biotech, a CDMO, agreed to collaborate on the manufacture of MinervaX’s active protein ingredients of its GBS vaccine. GBS reportedly is...
Related Services
AAV Packaging Services
READ MORE
Off-the-Shelf AAV Products
READ MORE
